Nefropatia por imunoglobulina A (IgA)

Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013 Jun 20;368(25):2402-14. Resumo

Trimarchi H, Barratt J, Cattran DC, et al; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017 May;91(5):1014-21. Resumo

Barratt J, Feehally J. Primary IgA nephropathy: new insights into pathogenesis. Semin Nephrol. 2011 Jul;31(4):349-60. Resumo

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4s):S1-S276.Texto completo  Resumo

Lv J, Zhang H, Wong MG, et al; TESTING Study Group. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017 Aug 1;318(5):432-42. Resumo

Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015 Dec 3;373(23):2225-36.Texto completo  Resumo

Tumlin JA, Hennigar RA. Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy. Semin Nephrol. 2004 May;24(3):256-68. Resumo

1. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013 Jun 20;368(25):2402-14. Resumo

2. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009 Sep;76(5):534-45. Resumo

3. Zeng CH, Le W, Ni Z, et al. A multicenter application and evaluation of the Oxford classification of IgA nephropathy in adult Chinese patients. Am J Kidney Dis. 2012 Nov;60(5):812-20. Resumo

4. Coppo R, Troyanov S, Bellur S, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014 Oct;86(4):828-36.Texto completo  Resumo

5. Herzenberg AM, Fogo AB, Reich HN, et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int. 2011 Aug;80(3):310-7. Resumo

6. Trimarchi H, Barratt J, Cattran DC, et al; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017 May;91(5):1014-21. Resumo

7. Haas M, Verhave JC, Liu ZH, et al. A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol. 2017 Feb;28(2):691-701. Resumo

8. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol. 2005 Jul;16(7):2088-97. Resumo

9. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002 Sep 5;347(10):738-48. Resumo

10. Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018 Sep;38(5):435-42.Texto completo  Resumo

11. McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011 Feb;26(2):414-30.Texto completo  Resumo

12. Kwon CS, Daniele P, Forsythe A, et al. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of Immunoglobulin A nephropathy. J Health Econ Outcomes Res. 2021;8(2):36-45.Texto completo  Resumo

13. Knoppova B, Reily C, King RG, et al. Pathogenesis of IgA nephropathy: current understanding and implications for development of disease-specific treatment. J Clin Med. 2021 Sep 29;10(19):4501.Texto completo  Resumo

14. Penfold RS, Prendecki M, McAdoo S, et al. Primary IgA nephropathy: current challenges and future prospects. Int J Nephrol Renovasc Dis. 2018;11:137-48.Texto completo  Resumo

15. Rodrigues JC, Haas M, Reich HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017 Apr 3;12(4):677-86.Texto completo  Resumo

16. Gharavi AG, Yan Y, Scolari F, et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet. 2000 Nov;26(3):354-7. Resumo

17. Bisceglia L, Cerullo G, Forabosco P, et al. Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. Am J Hum Genet. 2006 Dec;79(6):1130-4.Texto completo  Resumo

18. Paterson AD, Liu XQ, Wang K, et al. Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. J Am Soc Nephrol. 2007 Aug;18(8):2408-15.Texto completo  Resumo

19. Karnib HH, Sanna-Cherchi S, Zalloua PA, et al. Characterization of a large Lebanese family segregating IgA nephropathy. Nephrol Dial Transplant. 2007 Mar;22(3):772-7.Texto completo  Resumo

20. Kiryluk K, Li Y, Sanna-Cherchi S, et al. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet. 2012;8(6):e1002765.Texto completo  Resumo

21. Gharavi AG, Kiryluk K, Choi M, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011 Mar 13;43(4):321-7.Texto completo  Resumo

22. Feehally J, Farrall M, Boland A, et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol. 2010 Oct;21(10):1791-7.Texto completo  Resumo

23. Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014 Nov;46(11):1187-96.Texto completo  Resumo

24. Pouria S, Feehally J. Glomerular IgA deposition in liver disease. Nephrol Dial Transplant. 1999 Oct;14(10):2279-82. Resumo

25. Newell GC. Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis. Am J Kidney Dis. 1987 Mar;9(3):183-90. Resumo

26. Beaufils H, Jouanneau C, Katlama C, et al. HIV-associated IgA nephropathy - a post-mortem study. Nephrol Dial Transplant. 1995;10(1):35-8. Resumo

27. Katz A, Bargman JM, Miller DC, et al. IgA nephritis in HIV-positive patients: a new HIV-associated nephropathy? Clin Nephrol. 1992 Aug;38(2):61-8. Resumo

28. Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N Engl J Med. 1992 Sep 3;327(10):702-6.Texto completo  Resumo

29. Meadow SR, Scott DG. Berger disease: Henoch-Schönlein syndrome without the rash. J Pediatr. 1985 Jan;106(1):27-32. Resumo

30. Deltas C, Pierides A, Voskarides K. Molecular genetics of familial hematuric diseases. Nephrol Dial Transplant. 2013 Dec;28(12):2946-60.Texto completo  Resumo

31. Tomino Y. Pathogenesis of IgA nephropathy. Contrib Nephrol. 2007;157:1-7. Resumo

32. Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999 Jul;104(1):73-81. Resumo

33. Barratt J, Feehally J. Primary IgA nephropathy: new insights into pathogenesis. Semin Nephrol. 2011 Jul;31(4):349-60. Resumo

34. Lafayette RA, Kelepouris E. Immunoglobulin A nephropathy: advances in understanding of pathogenesis and treatment. Am J Nephrol. 2018;47 Suppl 1:43-52.Texto completo  Resumo

35. Yeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol. 2018 May;33(5):763-77.Texto completo  Resumo

36. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000 Aug;36(2):227-37. Resumo

37. Galla JH. IgA nephropathy. Kidney Int. 1995 Feb;47(2):377-87. Resumo

38. Murugapandian S, Mansour I, Hudeeb M, et al. Epidemiology of glomerular disease in southern Arizona: review of 10-year renal biopsy data. Medicine (Baltimore). 2016 May;95(18):e3633.Texto completo  Resumo

39. Narva AS. The spectrum of kidney disease in American Indians. Kidney Int Suppl. 2003 Feb;(83):S3-7.Texto completo  Resumo

40. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4s):S1-S276.Texto completo  Resumo

41. Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005 Sep-Oct;18(5):503-12. Resumo

42. Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001 Apr 15;110(6):434-7. Resumo

43. Barratt J, Feehally J, Smith AC. Pathogenesis of IgA nephropathy. Semin Nephrol. 2004 May;24(3):197-217. Resumo

44. Davin JC, Ten Berge IT, Weening JJ. What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis? Kidney Int. 2001 Mar;59(3):823-34. Resumo

45. Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis. 1997 Jun;29(6):829-42. Resumo

46. Iseki K, Miyasoto F, Uehara H, et al. Outcome study of renal biopsy patients in Okinawa, Japan. Kidney Int. 2004 Sep;66(3):914-9. Resumo

47. Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int. 2004 Sep;66(3):920-3. Resumo

48. Hasbargen JA, Copley JB. Utility of skin biopsy in the diagnosis of IgA nephropathy. Am J Kidney Dis. 1985 Aug;6(2):100-2. Resumo

49. Brenner BM, Levine SA. Brenner and Rector's the kdney. 7th ed. Boston, MA: Saunders; 2007:3072.

50. Boyd JK, Cheung CK, Molyneux K, et al. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int. 2012 May;81(9):833-43. Resumo

51. Floege J, Feehally J. Treatment of IgA nephropathy and Henoch-Schönlein nephritis. Nat Rev Nephrol. 2013 Jun;9(6):320-27. Resumo

52. Rosselli JL, Thacker SM, Karpinski JP, et al. Treatment of IgA nephropathy: an update. Ann Pharmacother. 2011 Oct;45(10):1284-96. Resumo

53. Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int. 2006 Jun;69(11):1939-44. Resumo

54. Barratt J, Feehally J. Treatment of IgA nephropathy. Kidney Int. 2006 Jun;69(11):1934-8. Resumo

55. Praga M, Gutiérrez E, González E, et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003 Jun;14(6):1578-83. Resumo

56. Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001 Jul;38(1):18-25. Resumo

57. Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999 Mar 13;353(9156):883-7. Resumo

58. Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004 Jan;15(1):157-63. Resumo

59. Lv J, X, Wang H. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol. 2012 Jun;23(6):1108-16. Resumo

60. Natale P, Palmer SC, Ruospo M, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2020 Mar 12;3:CD003965.Texto completo  Resumo

61. Lv J, Zhang H, Wong MG, et al; TESTING Study Group. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017 Aug 1;318(5):432-42. Resumo

62. Hou JH, Le WB, Chen N, et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis. 2017 Jun;69(6):788-95.Texto completo  Resumo

63. Xie Y, Chen X, Nishi S, et al. Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int. 2004 Apr;65(4):1135-44. Resumo

64. Reid S, Cawthon PM, Craig JC, et al. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD003962. Resumo

65. Chen Y, Tang Z, Wang Q, et al. Long-term efficacy of tonsillectomy in Chinese patients with IgA nephropathy. Am J Nephrol. 2007;27(2):170-75. Resumo

66. Hotta O, Miyazaki M, Furuta T, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001 Oct;38(4):736-43. Resumo

67. Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015 Dec 3;373(23):2225-36.Texto completo  Resumo

68. Liu LL, Wang LN, Liu LL, et al. Omega-3 fatty acids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials. Clin Nephrol. 2012 Feb;77(2):119-25. Resumo

69. Tumlin JA, Hennigar RA. Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy. Semin Nephrol. 2004 May;24(3):256-68. Resumo

70. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol. 2002 Jan;13(1):142-8. Resumo

71. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020 Oct 8;383(15):1436-46.Texto completo  Resumo

72. Wheeler DC, Toto RD, Stefánsson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021 Jul;100(1):215-24.Texto completo  Resumo

73. US National Library of Medicine. ClinicalTrials.gov. A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic kidney disease. Jan 2022 [internet publication].Texto completo

74. Smerud HK, Bárány P, Lindström K, et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant. 2011 Oct;26(10):3237-42.Texto completo  Resumo

75. Selvaskandan H, Cheung CK, Muto M, et al. New strategies and perspectives on managing IgA nephropathy. Clin Exp Nephrol. 2019 May;23(5):577-88.Texto completo  Resumo

76. Fellström BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017 May 27;389(10084):2117-27. Resumo

77. US National Library of Medicine. ClinicalTrials.gov. A randomized, multicenter, double-blind, parallel-group, active-control study of the efficacy and safety of sparsentan for the treatment of Immunoglobulin A nephropathy. June 2021 [internet publication].Texto completo

78. US National Library of Medicine. ClinicalTrials.gov. A phase 3, randomized, double-blind, placebo-controlled study of atrasentan in patients with IgA nephropathy at risk of progressive loss of renal function. Oct 2021 [internet publication].Texto completo

79. US National Library of Medicine. ClinicalTrials.gov. A randomized, double-blind, placebo-controlled, phase 3 study of the safety and efficacy of OMS721 in patients with Immunoglobulin A (IgA) nephropathy (ARTEMIS - IGAN). May 2019 [internet publication].Texto completo

80. US National Library of Medicine. ClinicalTrials.gov. A phase 2, randomized, double-blind, placebo-controlled study of cemdisiran in adult patients with IgA nephropathy. Dec 2021 [internet publication].Texto completo

81. US National Library of Medicine. ClinicalTrials.gov. An open-label phase 2a clinical study to evaluate the effectiveness and safety of IONIS-FB-LRx, an antisense inhibitor of complement factor B, in adult subjects with primary IgA nephropathy. Oct 2021 [internet publication].Texto completo

82. Gutiérrez E, Carvaca-Fontán F, Luzardo L, et al. A personalized update on IgA nephropathy: a new vision and new future challenges. Nephron. 2020;144(11):555-71.Texto completo  Resumo

83. US National Library of Medicine. ClinicalTrials.gov. An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients. July 2021 [internet publication].Texto completo

84. US National Library of Medicine. ClinicalTrials.gov. A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients. Dec 2021 [internet publication].Texto completo

85. Harris CL, Pouw RB, Kavanagh D, et al. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol. 2018 Oct;102:89-119.Texto completo  Resumo

86. US National Library of Medicine. ClinicalTrials.gov. A phase 1/2, multicenter trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BION-1301 in healthy volunteers and adults with IgA nephropathy. Dec 2021 [internet publication].Texto completo

87. US National Library of Medicine. ClinicalTrials.gov. A multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy and safety of VIS649 in participants with Immunoglobulin A (IgA) nephropathy. Sept 2021 [internet publication].Texto completo

88. Barbour SJ, Coppo R, Zhang H, et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019 Jul 1;179(7):942-52.Texto completo  Resumo

89. Beerman I, Novak J, Wyatt RJ, et al. The genetics of IgA nephropathy. Nat Clin Pract Nephrol. 2007 Jun;3(6):325-38. Resumo